Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? - Wikidata - wikimedia - TriplyDB

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

http://www.wikidata.org/entity/Q47174138

about

Early Relapse in Follicular Lymphoma: High Risks and High Stakes.Cancer Immunotherapy and the Immune Response in Follicular Lymphoma.

P2860

Q49895456-2227DBC5-3EBC-4463-984F-B74F71059FBA Q55442330-38F02DD6-5545-494F-9386-91F4580EFC39

P2860

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

http://www.wikidata.org/entity/Q47174138

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@en

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@nl

type

label

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@en

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@nl

prefLabel

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@en

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@nl

P1433

Q47174138-24FE7034-7832-43EF-8B55-675795CCB949

P1476

Q47174138-A9B07ACA-4CD5-408C-A82A-14BE0414F227

P2093

Q47174138-C9F500ED-20F7-42DC-B171-01CBC92BD421

Q47174138-D79D80F0-F2FD-490F-968C-DB37B782AF80

P2860

Q47174138-028668BF-52BA-40AF-BA98-B7320F5069C4

Q47174138-0325D1B6-CED1-4233-8AC2-309CC64F8DBB

Q47174138-124B7EAC-A4CD-4737-BA46-02F69976A552

Q47174138-13322E88-2186-41C6-8BD2-C1F4A1DDE5F4

Q47174138-1A351123-30BD-497F-9647-3ACFC17018FD

Q47174138-1CFDEFC7-6C59-45AE-A5CB-66977B5E4D84

Q47174138-1FC30C2D-E75E-4602-BA34-E7B1853E5B62

Q47174138-20D1A7A1-B48B-4FE0-9FC0-08D06D86F7E7

Q47174138-246E2269-D6F5-4B34-9DB7-67C0C392D0F4

Q47174138-2DA32356-6F72-477C-8C0C-32379984A904

P304

Q47174138-F683FB4A-5EEF-4D88-9BBA-DFC73154572B

P31

Q47174138-246F42A2-C52C-45D2-96AF-01B267328DAF

Q47174138-f9869ec3-93cd-4da6-8fd3-c05eb9b29057

P356

Q47174138-652DEE9F-F579-4ED0-A388-631BD8EAEF63

P407

Q47174138-5CC3A676-8DA3-45AA-9401-F17E063936C1

P433

Q47174138-CA731911-0A11-4C00-A053-C53F1ED8B47D

P478

Q47174138-3B94C0CE-AC70-4C54-BBCE-D9581E537383

P577

Q47174138-29B906E8-1D0C-4083-A9B7-3759915F66F6

P698

Q47174138-2EC1236B-F18F-4AB1-B79F-658E17CF6674

P932

Q47174138-20B80618-E12F-4195-A41B-CE9784BF9E81

P356

JOP.2017.026336

P1433

Journal of Oncology Practice

P1476

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

@en

P2093

Mary M Horowitz

http://www.w3.org/2001/XMLSchema#string

Mehdi Hamadani

http://www.w3.org/2001/XMLSchema#string

P2860

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

P304

798-806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2017.026336

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29232542

http://www.w3.org/2001/XMLSchema#string

P932

5728364

http://www.w3.org/2001/XMLSchema#string